Background
==========

The reconstruction of signal transduction networks is intensively applied in different fields of biomedicine, particularly, for identification of promising drug targets. Designed for biological network analysis databases support the effective integration of huge data obtained in large-scale experiments \[[@B1],[@B2]\]. However, the experimentally derived data has many gaps, which lead to difficulties in simulating the cell signaling pathways. This problem can be settled by the network enrichment with predicted interactions. In this study we propose to apply the previously published method PAAS (Projection of Amino Acid Sequences) \[[@B3],[@B4]\] for the enrichment of signal transduction networks through the recognition of proteins phosphorylated by certain kinases. We applied PAAS method to TRANSPATH^®^database to estimate its efficiency and to predict of the new interactions that could be used for the enrichment of signal transduction networks. The TRANSPATH^®^database is manually curated information resource providing both specific and general information on signal transduction that can has also the means for network analysis \[[@B5]\]. TRANSPATH^®^database is one of the most comprehensive collections of experimentally verified data on signal transduction in eukaryotic cells. Still, many signaling interactions in various cell types are not documented in TRANSPATH^®^. This gap of knowledge can hamper the analysis of signaling networks and the prediction of functionally important elements. We suppose that addition of interactions predicted by the algorithm presented here will be useful for filling up of these gaps.

Several bioinformatics approaches were applied for prediction of the new functional characteristics of proteins with the aim of determination of new network nodes and edges \[[@B6]\]. Using the predictive tools one can significantly enrich the database and reconstruct more relevant models. It allows detection of promising drug targets.

Several well known algorithms use the network context information based on the protein location in the network \[[@B6]\] and on the comparison of the networks constructed for different species \[[@B7]\]. Frequently, such context information is very sparse. The amino acid sequences of proteins can serve as an important informational source for increasing the reliability of predicted proteins that participate in signal transduction.

The signaling network can be represented as a series of protein-protein interactions; therefore, the methods for prediction of the interacting protein pairs can also be used for the network enrichment. Some methods are based on the calculation of co-variation of positional substitutions in aligned sequences of interacting protein families \[[@B8]\]. In other methods, the members of the query pair are compared to the training set with the known protein interactions \[[@B9]\]. PIPE-like methods \[[@B10]\] calculate the similarity of short regions for the input sequence pair and the training sets and estimate the putative interactions based on the resulting matrix with the number of matches above the given threshold included. PPI-SP method is also based on the sequence comparison, but each input sequence pair is represented as vector of similarity scores calculated by the Smith-Waterman alignment \[[@B11]\]. The prediction of interacting pairs is performed by SVM algorithm.

In the sequence-based method for prediction of protein-protein interactions the both members of each pair are compared with the sets of sequences of known interacting proteins. We used an original sequence-based method of protein classification PAAS \[[@B3],[@B4]\]. In this study the training set consisted of the known protein kinase substrates, classified according to the kinase types that can be considered as recognition of substrate specificity class using only the substrate sequences. PAAS method \[[@B3],[@B4]\] is particularly appropriate for the situation when the single kinase phosphorylates many different substrates and, therefore, participates in many pathways. So, the suggested method can be applied in wide area of signal transduction pathways.

Generally, the proposed positional score is close to the measures used in other approaches - summation of weights of coincided positions (e.g. BLOSUM or PAM matrices) over the sliding window. All such methods require the shifting of sequences to each other. The more sophisticated local alignment procedure can also be considered as merging the local un-gapped similarities. Unlike other algorithms, in our approach the projection scores are assigned to each position of the query sequence. The maximal value of scores is calculated for all regions containing this position. It resembles the local alignment algorithm with more simple realization. The training sequences are projected onto the query sequence, and the summarized values obtained for all positions and all training set classes are the input to the classifier. This simple procedure does not require the large memory space. Unlike the methods based on the algorithmic alignment, PAAS algorithm does not contain the time-consuming steps.

It was shown that PAAS provides high accuracy of the functional class prediction composed of homologous amino acid sequences revealing the global sequence similarity. The proteins interacting with the same protein partner can also be characterized by the global sequence similarity. However, in many cases the proteins reveal only the local similarity. We consider that the proposed approach can be useful for determination of the proteins in the interaction network.

The proposed approach was applied for prediction of new interactions in protein phosphorylation networks. The interaction cascades between protein kinases and their substrates play a key role in cell cycle regulation, in the normal and tumor cells \[[@B12]\]. Protein phosphorylation (including substrate specificity of different protein kinase types, phosphorylated peptides and regions responsible for kinase-substrate binding) is well studied, providing a lot of information necessary for the evaluation and improvement of the method. The proteins included into the training set were classified according to the kinase\'s specificity, so that each class consisted of the proteins phosphorylated by the same kinase.

The common approach for prediction of protein kinase substrates involves the recognition of specific regions in amino acid sequences. The data set of experimentally determined phosphorylated peptides is used to compose the sequence motifs surrounding the modified Thr, Ser or Tyr residues. However, the phosphorylation motifs are not sufficient for provision of strongly specific interaction of the kinase and its substrates. The additional regions located in the substrate proteins are responsible for the enzyme recruitment, i.e. for increasing the probability of binding between kinase and substrate \[[@B13]\].

The algorithms based on the recognition of phosphorylation motifs and other interaction regions are used for searching of these motifs in the annotated sequences. The software like ScanSite \[[@B14]\], NetPhosK \[[@B15]\], PredPhospho \[[@B16]\] use the different mathematical approaches including Hidden Markov Models or Support Vector Machine. They provide the prediction of the substrates of certain kinases with high accuracy on the basis of sequence mapping \[[@B17]\]. In contrast to the above mentioned methods the data from the signal transduction networks frequently do not allow to make the sequence mapping. In this study we investigated the efficiency of our approach, if the amino acid sequences of training set were not mapped.

At the first stage of this study, we validated PAAS method on the basis of the known kinase-substrate interactions. At the second stage, we applied the suggested approach for prediction of new interactions for the proteins stored in TRANSPATH^®^database. At the third stage, the predicted interactions were used for the enrichment of network. It helped us to reconstruct potential cell signaling cascades.

Methods
=======

Sequence local similarity score
-------------------------------

In PAAS algorithm, the query amino acid sequence is described by the series of local similarity scores \[[@B3]\]. These values are defined by shifting the sequence *D*(retrieved from the training dataset) versus the query sequence *Q*(Figure [1](#F1){ref-type="fig"}). The score of similarity with the sequence *D*is calculated for each position *i*of sequence *Q*as follows:

![**Local similarity estimation**. The diagonal corresponds to the shift value *h*providing the best match between the region of sequence *Q*and sequence *D*. *A*~*mn*~is the summarized similarity of superposed areas of sequences *Q*and *D*terminated at *q*~*m*~and *d*~*n+h*~, respectively. Thus, the score *R*~*i*~= *A*~*ih*~- *A*~*i-F,\ h*~, presents the highest similarity score being found for the selected region of sequence *Q*. Finally, the similarity score S~*i*~takes the maximal values from *R*~*i+j*~scores.](1471-2105-11-313-1){#F1}

where *sim(q, d)*is the similarity of superposed amino acid residues according to the given measure - e.g. the residue identity or substitution matrix; *q*~*x*~and *d*~*y*~are the residues in the indexed positions of *Q*and *D*, respectively; *h*is the current shift value; *F*is the value given by the parameter \"frame\"; *R*~*i*~is the score of maximal similarity of the sequence *Q*region (equal *F*in length and terminated at position *i*upright) with sequence *D*; *S*~*i*~is defined as maximal value of scores *R*~*i+j*~calculated for all regions, which include the position *i*.

In this study, all sequence comparisons were performed by residue similarity measure on the basis of Blosum62 matrix \[[@B18]\].

Prediction algorithm
--------------------

We used the algorithm described in detail in our previous publications \[[@B3],[@B4]\]. The query sequence *Q*is compared to each sequence of the training set. Thus, we obtained the local similarity scores for the sequence *Q*with all training sequences. These values were used as the input data for the classifier. Belonging of the query protein *Q*to class *C*is estimated by special statistic *B~Q~(C)*\[[@B3],[@B19]-[@B22]\] calculated as follows:

where *N*is a number of amino acid sequences in the training set; *W~k~(C)*and *W~k~(¬C)*are the weights of the *k*^*th*^training sequence in class *C*and its complement (in simplest case takes the value 0 or 1), *S*~*ik*~is a similarity score in position *i*of the query sequence with the *k*^*th*^training sequence, *n*is a number of amino acid residues in the sequence *Q*.

The qualitative results of prediction (\"belong or not belong\") are calculated for each class of proteins. The prediction result is presented in PAAS by the list of classes with the probabilities of belonging to the particular class and its complement - *P*~1~and *P*~0,~respectively. *P*~1~and *P*~0~are the functions of *B-*statistic for the query sequence. The list is arranged in descending order of *P*~1~-*P*~0~; thus, the more significant results are at the top of the list. The default cut-off is *P*~1~\> P~0~.

The relationships necessary for estimating the *P*~1~and *P*~0~probabilities, are determined by Leave-One-Out Cross-Validation (LOO CV) procedure as follows. One sequence is removed from the training set and is used as the query set. The *B-*statistic values are calculated for each class *C*of the training set. The procedure is repeated for each sequence of the training set. Using the calculated *B-*statistic values, smooth estimations of the distribution functions *P~1~(B)*and *P~0~(B)*are obtained for each class \[[@B19],[@B20]\]. Substituting the arguments for *B~Q~(C)*we can estimate the probability of the query protein belonging to the given class. This training procedure enables to save statistical model, which can be used for the estimation of new proteins.

Evaluation of prediction accuracy
---------------------------------

LOO CV and multiple splitting of the initial data on the training and test sets with calculation of Invariant Accuracy of Prediction (*IAP*) criterion were used for the evaluation of prediction accuracy. IAP is calculated as the ratio between the number of correctly classified pairs and that of all possible pairs \[[@B20],[@B22]\]:

Mathematically, IAP value is equal to the sample estimation of the probability when the classifier ranks of the randomly chosen member *M*for the given class *C*are higher than the randomly chosen member *U*of the class complement ¬*C*. Formally, IAP criterion coincides with the Area Under the ROC Curve (AUC), which is very popular for the accuracy evaluation \[[@B23]\], but calculation of the IAP criterion is more simple.

Data on protein kinase substrates
---------------------------------

The substrates of different protein kinase types, phosphorylating the Ser/Thr and Tyr residues were studied. Phospho.ELM database \[[@B24]\] was chosen as the source of information with experimentally confirmed protein substrates of the known Ser/Thr and Tyr protein kinases. We selected the substrates of 45 protein kinase types: each class of kinase-specificity contained at least 10 proteins. The list of selected proteins (as designated in Phospho.ELM is presented in Table [1](#T1){ref-type="table"}.

###### 

Designations and descriptions of kinases whose substrates were included into the training set

  Kinase type     Description                                                                  **L**~**min**~   **L**~**max**~
  --------------- ---------------------------------------------------------------------------- ---------------- ----------------
  ABL1            Proto-oncogene tyrosine-protein kinase                                       178              1271
                                                                                                                
  ATM             Ataxia telangiectasia mutated                                                118              3056
                                                                                                                
  AURORA_A        Serine/threonine-protein kinase 6 (STK6)                                     136              1863
                                                                                                                
  AURORA_B        Serine/threonine-protein kinase 12 (AURKB)                                   136              923
                                                                                                                
  CAM_KII_group   Calcium/calmodulin-dependent protein kinase II                               52               5037
                                                                                                                
  CAM_KII_alpha   Calcium/calmodulin-dependent protein kinase II alpha                         52               4967
                                                                                                                
  CDK1            Cell division control protein 2 homolog (Cyclin-dependent kinase 1)          107              4684
                                                                                                                
  CDK2            Cell division protein kinase 2                                               119              1971
                                                                                                                
  CDKgroup        Cyclin-dependent kinases                                                     149              1863
                                                                                                                
  CK1alpha        Casein kinase 1, alpha                                                       140              911
                                                                                                                
  CK1group        Casein kinases 1                                                             195              2843
                                                                                                                
  CK2group        Casein kinase 2                                                              98               2346
                                                                                                                
  DNA_PK          DNA-dependent protein kinase catalytic subunit                               270              4128
                                                                                                                
  EGFR            Epidermal growth factor receptor (Receptor tyrosine-protein kinase ErbB-1)   76               1291
                                                                                                                
  ERK2            Mitogen-activated protein kinase 1                                           196              2225
                                                                                                                
  ERK1            Mitogen-activated protein kinase 3                                           168              2749
                                                                                                                
  FYN             Proto-oncogene tyrosine-protein kinase Fyn                                   164              2758
                                                                                                                
  GSK3beta        Glycogen synthase kinase 3 beta                                              164              2470
                                                                                                                
  GSKgroup        Glycogen synthase kinases 3                                                  157              1914
                                                                                                                
  INS_R           Insulin receptor                                                             132              1382
                                                                                                                
  JNK1            c-Jun N-terminal kinase 1                                                    196              1242
                                                                                                                
  JNK2            c-Jun N-terminal kinase 2                                                    196              1075
                                                                                                                
  LCK             Lymphocyte-specific protein tyrosine kinase                                  220              2472
                                                                                                                
  LKB1            Serine/threonine kinase 11 (LKB1)                                            433              1263
                                                                                                                
  LYN             Tyrosine-protein kinase Lyn                                                  202              1827
                                                                                                                
  MAPKAPK2        mitogen-activated protein kinase-activated protein kinase 2                  168              1807
                                                                                                                
  MAPKgroup       P38, JNK and ERK                                                             136              1914
                                                                                                                
  PAK1            Serine/threonine-protein kinase PAK1                                         89               2647
                                                                                                                
  PDK-1           3-phosphoinositide dependent protein kinase 1                                268              1374
                                                                                                                
  PKAalpha        Protein kinase, cAMP-dependent, catalytic, alpha                             52               2749
                                                                                                                
  PKAgroup        cAMP-dependent protein kinase                                                30               5037
                                                                                                                
  PKBgroup        Protein kinases B                                                            130              5890
                                                                                                                
  PKCalpha        Protein kinase C, alpha type                                                 72               2441
                                                                                                                
  PKCbeta         Protein kinase C, beta 1                                                     149              1531
                                                                                                                
  PKCdelta        Protein kinase C, delta type                                                 187              2414
                                                                                                                
  PKCgroup        Protein kinase                                                               30               2442
                                                                                                                
  PKCzeta         Protein kinase C, zeta type                                                  147              1242
                                                                                                                
  PKGgroup        cGMP-dependent protein kinases                                               90               5037
                                                                                                                
  PLK1            Polo like kinase 1                                                           163              3418
                                                                                                                
  ROCKgroup       Rho-associated, coiled-coil containing protein kinases                       309              737
                                                                                                                
  RSKgroup        Ribosomal protein S6 kinases                                                 198              2647
                                                                                                                
  SGKgroup        Serum/glucocorticoid regulated kinase                                        341              3144
                                                                                                                
  SRC             Proto-oncogene tyrosine-protein kinase Src                                   101              4544
                                                                                                                
  SYK             Tyrosine-protein kinase SYK (Spleen tyrosine kinase).                        113              1290
                                                                                                                
  P38alpha        mitogen-activated protein kinase 14                                          168              902

L~min~and L~max~are the minimal and maximal values of the sequence length of proteins referred to the given class.

The UniProt accession numbers of protein substrates were retrieved from Phospho.ELM and the corresponding sequences were included into the non-redundant dataset of 1021 proteins. The obtained training set contained the proteins of the following species: the major part (971) belonged to the mammals including 709 human proteins; the remaining sequences related to other vertebrata, fungi, viruses and insects. Thus, 45 intersecting kinase specificity classes were composed (each class contained at least 10 proteins). As can be seen from Table [1](#T1){ref-type="table"}, the sequence length significantly varies within each class. The average number of kinase types per one substrate protein was 1.6. The distribution of the number of kinase types per substrate is shown in Figure [2](#F2){ref-type="fig"}.

![**Intersection of the kinase substrate classes**.](1471-2105-11-313-2){#F2}

The certain classes were the subgroups of other classes (e.g. CDK1 and CDK2 are subclasses of CDKgroup). Sequence set of the class cannot completely cover the sets of subclasses that is typical for biological databases.

External validation set
-----------------------

For further prediction, we selected 186 proteins from the commercial version of TRANSPATH^®^database (release 2009.2) not included in the training set as a test set. It is known that the substrates of kinases are involved in various important processes, like carcinogenesis, inflammation, apoptosis, etc. Therefore, the prediction of the new interactions wherein the proteins from the test set could be involved is interesting for further investigations of the appropriate processes.

Reconstruction of signal transduction pathways
----------------------------------------------

We applied the ExPlain™ software, version 2.4.1 \[[@B25]\], which can be used for the iterative building of the signal transduction cascades on the basis of full network from TRANSPATH^®^database and the shortest path algorithm. The microarray data published by Viemann et al. \[[@B26]\] were also used in the study.

Microarray data
---------------

We have analyzed the microarray gene expression data on TNF-alpha stimulation of primary human endothelial cells (HUVEC) taken from GEO (GSE2639) \[[@B26]\]. Gene expression profiles were measured by Affymetrix^®^GeneChip^®^Human Genome U133A array in HUVEC, stimulated for 5 hours with TNF, and in untreated HUVEC too. Four repeated experiments were used for each condition. We applied the criteria of at least two-fold change in gene expression and *p*-value \< 0.01 revealed by *t*-test. The expression of 74 genes appeared to be significantly higher after TNF-alpha treatment.

Results
=======

Leave-one-out cross-validation
------------------------------

LOO CV procedure was performed for the set of 1021 amino acid sequences of protein kinase substrates assigned for 45 classes. The results obtained for different frame values are given in Table [2](#T2){ref-type="table"}.

###### 

IAP values obtained by LOO CV for the training set

  Kinase type       Number of substrates   Frame values                                                       
  ----------------- ---------------------- -------------- ------- ------- --------- --------- ------- ------- -------
  ABL1              32                     0.652          0.665   0.672   0.661     0.675     0.685   0.683   0.664
                                                                                                              
  ATM               30                     0.787          0.780   0.786   0.779     0.785     0.781   0.782   0.786
                                                                                                              
  AURORA_A          12                     0.747          0.732   0.743   0.792     0.784     0.773   0.769   0.744
                                                                                                              
  AURORA_B          14                     0.857          0.840   0.819   0.858     0.871     0.879   0.871   0.876
                                                                                                              
  CAM_II_group      40                     0.689          0.708   0.699   0.707     0.680     0.692   0.693   0.703
                                                                                                              
  *CAM_KII_alpha*   21                     0.616          0.592   0.591   *0.531*   *0.532*   0.528   0.519   0.529
                                                                                                              
  CDK1              69                     0.640          0.645   0.641   0.648     0.656     0.657   0.662   0.658
                                                                                                              
  CDK2              28                     0.767          0.747   0.754   0.761     0.753     0.748   0.730   0.725
                                                                                                              
  CDKgroup          47                     0.693          0.715   0.702   0.682     0.664     0.663   0.667   0.670
                                                                                                              
  CK1alpha          11                     0.578          0.553   0.575   0.609     0.625     0.642   0.594   0.560
                                                                                                              
  CK1group          18                     0.642          0.644   0.639   0.637     0.627     0.630   0.660   0.662
                                                                                                              
  CK2group          122                    0.745          0.740   0.735   0.746     0.742     0.737   0.742   0.748
                                                                                                              
  *DNA_PK*          11                     0.492          0.506   0.458   *0.508*   *0.529*   0.563   0.537   0.545
                                                                                                              
  EGFR              27                     0.840          0.843   0.883   0.861     0.893     0.887   0.891   0.888
                                                                                                              
  ERK2              71                     0.714          0.700   0.695   0.697     0.698     0.700   0.696   0.702
                                                                                                              
  ERK1              61                     0.655          0.639   0.634   0.632     0.632     0.631   0.622   0.634
                                                                                                              
  FYN               25                     0.687          0.697   0.695   0.696     0.651     0.627   0.619   0.632
                                                                                                              
  GSK3beta          26                     0.654          0.661   0.690   0.688     0.706     0.718   0.716   0.725
                                                                                                              
  GSKgroup          20                     0.650          0.640   0.664   0.616     0.589     0.592   0.557   0.566
                                                                                                              
  INS_R             13                     0.709          0.641   0.643   0.685     0.668     0.632   0.623   0.569
                                                                                                              
  JNK1              20                     0.762          0.773   0.754   0.766     0.783     0.770   0.777   0.779
                                                                                                              
  JNK2              10                     0.672          0.631   0.605   0.653     0.632     0.599   0.638   0.655
                                                                                                              
  LCK               29                     0.813          0.820   0.831   0.824     0.826     0.834   0.838   0.835
                                                                                                              
  LKB1              16                     0.996          0.995   0.994   0.994     0.993     0.989   0.990   0.991
                                                                                                              
  LYN               26                     0.751          0.771   0.743   0.722     0.705     0.706   0.711   0.712
                                                                                                              
  MAPKAPK2          17                     0.618          0.637   0.629   0.641     0.571     0.542   0.511   0.522
                                                                                                              
  MAPKgroup         36                     0.677          0.664   0.676   0.676     0.666     0.668   0.665   0.669
                                                                                                              
  *PAK1*            21                     0.500          0.517   0.570   *0.573*   *0.569*   0.575   0.576   0.541
                                                                                                              
  PDK-1             24                     0.957          0.958   0.956   0.957     0.955     0.948   0.949   0.950
                                                                                                              
  *PKAalpha*        22                     0.367          0.356   0.356   *0.409*   *0.388*   0.424   0.420   0.398
                                                                                                              
  PKAgroup          206                    0.658          0.660   0.669   0.668     0.672     0.648   0.646   0.648
                                                                                                              
  PKBgroup          63                     0.663          0.676   0.661   0.655     0.640     0.630   0.637   0.637
                                                                                                              
  PKCalpha          81                     0.663          0.653   0.656   0.643     0.646     0.649   0.656   0.653
                                                                                                              
  *PKCbeta*         10                     0.294          0.376   0.350   *0.364*   *0.415*   0.475   0.481   0.427
                                                                                                              
  *PKCdelta*        17                     0.418          0.472   0.449   *0.490*   *0.489*   0.463   0.479   0.493
                                                                                                              
  PKCgroup          145                    0.733          0.744   0.754   0.757     0.756     0.724   0.724   0.725
                                                                                                              
  PKCzeta           11                     0.643          0.626   0.668   0.701     0.736     0.746   0.743   0.733
                                                                                                              
  *PKGgroup*        10                     0.492          0.505   0.553   *0.551*   *0.594*   0.606   0.587   0.548
                                                                                                              
  PLK1              18                     0.678          0.628   0.670   0.718     0.731     0.721   0.688   0.704
                                                                                                              
  ROCKgroup         12                     0.828          0.852   0.862   0.856     0.866     0.872   0.880   0.889
                                                                                                              
  RSKgroup          18                     0.592          0.592   0.618   0.658     0.645     0.626   0.620   0.640
                                                                                                              
  SGKgroup          11                     0.738          0.749   0.699   0.695     0.699     0.699   0.699   0.683
                                                                                                              
  SRC               92                     0.731          0.732   0.740   0.742     0.742     0.738   0.746   0.745
                                                                                                              
  SYK               21                     0.741          0.729   0.752   0.766     0.775     0.764   0.744   0.750
                                                                                                              
  P38alpha          24                     0.726          0.720   0.723   0.737     0.741     0.728   0.705   0.717
                                                                                                              
  Average                                  0.678          0.678   0.681   0.689     0.689     0.687   0.683   0.681

Table [2](#T2){ref-type="table"} shows that the highest average accuracy was reached at the frame equal to 25 or 30 residues. Thirty eight classes of kinase specificity were recognized with the reasonable accuracy. Seven classes (in italics) were recognized with IAP values less 0.6.

Validation with multiple splitting
----------------------------------

The procedure of multiple splitting of the initial data on the training and test sets (2/3 and 1/3, respectively) was applied for the estimation of the robustness of PAAS method. In this test we have used the total evaluation set of 1021 sequences, which represents the substrates of 45 kinase types. The subset of 907 human proteins was also used in the study. Twenty random divisions were made for each kinase type with the frame value = 25. The results are shown in Table [3](#T3){ref-type="table"}.

###### 

IAP values obtained by 20-fold multiple splitting

  Kinase type     All species   Human                                         
  --------------- ------------- ------- ------- ------- ----- ------- ------- -------
  ABL1            32            0.661   0.685   0.072   24    0.600   0.600   0.106
                                                                              
  ATM             30            0.779   0.751   0.086   29    0.771   0.762   0.075
                                                                              
  AURORA_A        12            0.792   0.777   0.130   \-                    
                                                                              
  AURORA_B        14            0.858   0.857   0.114   11    0.808   0.815   0.115
                                                                              
  CAM_II_group    40            0.707   0.657   0.084   19    0.651   0.681   0.090
                                                                              
  CAM_KII_alpha   21            0.531   0.515   0.120   16    0.475   0.494   0.111
                                                                              
  CDK1            69            0.648   0.641   0.049   62    0.679   0.653   0.064
                                                                              
  CDK2            28            0.761   0.740   0.066   21    0.659   0.666   0.092
                                                                              
  CDKgroup        47            0.682   0.653   0.065   30    0.546   0.534   0.080
                                                                              
  CK1alpha        11            0.609   0.595   0.134   10    0.548   0.535   0.097
                                                                              
  CK1group        18            0.637   0.622   0.158   10    0.487   0.508   0.182
                                                                              
  CK2group        122           0.746   0.734   0.041   87    0.680   0.670   0.046
                                                                              
  DNA_PK          11            0.508   0.466   0.121   \-                    
                                                                              
  EGFR            27            0.861   0.808   0.090   21    0.723   0.728   0.092
                                                                              
  ERK1            71            0.697   0.624   0.048   54    0.621   0.637   0.054
                                                                              
  ERK2            61            0.632   0.673   0.038   52    0.662   0.656   0.048
                                                                              
  FYN             25            0.696   0.726   0.083   19    0.625   0.664   0.096
                                                                              
  GSK3beta        26            0.688   0.671   0.087   20    0.606   0.588   0.125
                                                                              
  GSKgroup        20            0.616   0.599   0.113   13    0.648   0.620   0.183
                                                                              
  INS_R           13            0.685   0.583   0.133   \-                    
                                                                              
  JNK1            20            0.766   0.763   0.093   15    0.786   0.759   0.121
                                                                              
  JNK2            10            0.653   0.634   0.125   \-                    
                                                                              
  LCK             29            0.824   0.795   0.058   24    0.787   0.792   0.072
                                                                              
  LKB1            16            0.994   0.993   0.003   15    0.995   0.995   0.005
                                                                              
  LYN             26            0.722   0.745   0.090   20    0.699   0.691   0.118
                                                                              
  MAPKAPK2        17            0.641   0.652   0.082   15    0.590   0.596   0.081
                                                                              
  MAPKgroup       36            0.676   0.661   0.063   31    0.625   0.614   0.089
                                                                              
  PAK1            21            0.573   0.574   0.098   16    0.527   0.514   0.092
                                                                              
  PDK-1           24            0.957   0.956   0.038   19    0.942   0.933   0.079
                                                                              
  PKAalpha        22            0.409   0.466   0.108   \-                    
                                                                              
  PKAgroup        206           0.668   0.655   0.028   138   0.595   0.593   0.037
                                                                              
  PKBgroup        63            0.655   0.650   0.051   55    0.625   0.624   0.038
                                                                              
  PKCalpha        81            0.643   0.627   0.054   68    0.648   0.630   0.053
                                                                              
  PKCbeta         10            0.364   0.383   0.155   \-                    
                                                                              
  PKCdelta        17            0.49    0.507   0.111   16    0.382   0.439   0.115
                                                                              
  PKCgroup        145           0.757   0.755   0.036   84    0.691   0.656   0.046
                                                                              
  PKCzeta         11            0.701   0.670   0.207   10    0.646   0.584   0.170
                                                                              
  PKGgroup        10            0.551   0.642   0.187   \-                    
                                                                              
  PLK1            18            0.718   0.661   0.163   17    0.699   0.669   0.119
                                                                              
  ROCKgroup       12            0.856   0.839   0.155   \-                    
                                                                              
  RSKgroup        18            0.658   0.644   0.095   14    0.471   0.511   0.146
                                                                              
  SGKgroup        11            0.695   0.685   0.182   10    0.600   0.543   0.159
                                                                              
  SRC             92            0.742   0.717   0.043   65    0.656   0.627   0.052
                                                                              
  SYK             21            0.766   0.709   0.158   17    0.689   0.615   0.179
                                                                              
  p38alpha        24            0.737   0.700   0.083   23    0.767   0.786   0.065
                                                                              
  Average                       0.689   0.677   0.096         0.654   0.648   0.094

The calculation was performed for the whole training set (1021 substrate proteins) and subset, including only human proteins (709). The numbers of the substrates in each class (No) are presented. IAP values were calculated by LOO CV procedure. The IAP values, averaged on 20 rounds of multiple splitting (M) and their standard deviations (SD), are presented. The kinase substrate classes containing less than 10 proteins (for human) are excluded.

Average IAP values for LOO CV and multiple splitting are sufficiently close to each other proving the robustness of the approach.

Prediction for proteins from TRANSPATH^®^
-----------------------------------------

The training set of 1021 substrates of kinases with the frame value = 25 was used for prediction of 186 proteins from the external validation set. All results, wherein *P*~1~value exceeded *P*~0~value, were considered as the putative substrates of kinases. 38 types of kinases from the training set with IAP value \> 0.6 were selected for further investigation.

With the threshold *P*~1~\> *P*~0~, 2656 kinase-substrate interactions for 38 selected types of kinases were predicted for the test set. We found 55 phosphorylation reactions related to 30 proteins from TRANSPATH^®^set (substrates) and to the studied kinase types. Table [4](#T4){ref-type="table"} displays 44 correctly predicted interactions mentioned in TRANSPATH^®^annotations. Thus, the prediction accuracy for the independent external test set was 80% (44 confirmed reactions of 55).

###### 

The confirmation of TRANSPATH^®^interaction data with the PAAS prediction

  Substrate Accession No in UniProt   Substrate Name in TRANSPATH^®^database   Kinase type   ***P***~**1**~-***P***~**0**~   IAP\*
  ----------------------------------- ---------------------------------------- ------------- ------------------------------- -------
  O15169                              Axin                                     CK1group      \-                              0.637
                                                                                                                             
  O15169                              Axin                                     GSK3beta      0.844                           0.688
                                                                                                                             
  O15169                              Axin                                     Cdk\*         0.031                           0.682
                                                                                                                             
  P24941                              Cdk2                                     Lyn           0.525                           0.722
                                                                                                                             
  P17302                              Connexin-43                              Src           0.754                           0.742
                                                                                                                             
  P17302                              Connexin-43                              PKCgroup\*    0.863                           0.757
                                                                                                                             
  P17302                              Connexin-43                              PKCalpha      0.342                           0.643
                                                                                                                             
  Q13158                              FADD                                     PKCgroup\*    0.446                           0.757
                                                                                                                             
  Q13158                              FADD                                     CK1alpha      \-                              0.609
                                                                                                                             
  P05230                              FGF-1                                    CK2group      \-                              0.746
                                                                                                                             
  P43694                              GATA-4                                   ERK2          0.915                           0.697
                                                                                                                             
  P43694                              GATA-4                                   GSK3beta      0.688                           0.688
                                                                                                                             
  Q16665                              HIF-1alpha                               ERK1          0.038                           0.632
                                                                                                                             
  Q16665                              HIF-1alpha                               ERK2          \-                              0.697
                                                                                                                             
  Q01344                              IL-5Ralpha                               Lyn           0.153                           0.722
                                                                                                                             
  P17535                              JunD                                     ERK2          0.749                           0.697
                                                                                                                             
  P17535                              JunD                                     JNK2          0.686                           0.653
                                                                                                                             
  P17535                              JunD                                     JNK1          0.642                           0.766
                                                                                                                             
  Q13233                              MEKK1                                    ABL1l         0.044                           0.661
                                                                                                                             
  Q13233                              MEKK1                                    PKCgroup      \-                              0.757
                                                                                                                             
  Q13233                              MEKK1                                    GSKgroup\*    0.371                           0.616
                                                                                                                             
  O15151                              Mdm4                                     CK1alpha      0.183                           0.609
                                                                                                                             
  O15151                              Mdm4                                     ATM           0.818                           0.779
                                                                                                                             
  P27361                              ERK1                                     Lck           \-                              0.824
                                                                                                                             
  P27361                              ERK1                                     MAPKgroup     0.627                           0.824
                                                                                                                             
  Q16539                              p38alpha                                 p38aplha      0.482                           0.737
                                                                                                                             
  Q13469                              NF-AT1                                   JNK1          0.301                           0.766
                                                                                                                             
  Q13469                              NF-AT1                                   CK1group      0.664                           0.637
                                                                                                                             
  Q13469                              NF-AT1                                   PKCzeta       0.193                           0.701
                                                                                                                             
  P16234                              PDGFRalpha                               ABL1          0.305                           0.661
                                                                                                                             
  P09619                              PDGFRbeta                                ABL1          0.468                           0.661
                                                                                                                             
  P53350                              Plk1                                     Cdk1          \-                              0.648
                                                                                                                             
  P53350                              Plk1                                     PKAgroup      \-                              0.668
                                                                                                                             
  P28749                              p107                                     CDKgroup\*    0.636                           0.682
                                                                                                                             
  Q13309                              Skp2                                     Cdk2          0.249                           0.761
                                                                                                                             
  Q9Y6H5                              Synphilin-1                              GSK3Beta      0.709                           0.688
                                                                                                                             
  Q9Y6H5                              Synphilin-1                              CK2group      0.429                           0.746
                                                                                                                             
  Q93038                              DR3                                      ERK2          0.617                           0.697
                                                                                                                             
  P10276                              RAR-alpha                                MAPKgroup\*   0.845                           0.676
                                                                                                                             
  P10276                              RAR-alpha                                PKCgroup      \-                              0.757
                                                                                                                             
  P23771                              GATA-3                                   MAPKgroup\*   0.536                           0.676
                                                                                                                             
  P29353                              Shc-1                                    Src           0.881                           0.742
                                                                                                                             
  P29353                              Shc-1                                    ABL1          0.456                           0.661
                                                                                                                             
  P29353                              Shc-1                                    JNK1          0.126                           0.766
                                                                                                                             
  P29353                              Shc-1                                    MAPKgroup     0.028                           0.676
                                                                                                                             
  P29353                              Shc-1                                    Lyn           0.013                           0.722
                                                                                                                             
  P29353                              Shc-1                                    RSKgroup      \-                              0.658
                                                                                                                             
  P35228                              NOS2                                     ERK1          \-                              0.632
                                                                                                                             
  Q07812                              Bax                                      PKBgroup\*    0.850                           0.655
                                                                                                                             
  Q07812                              Bax                                      JNK1          0.619                           0.766
                                                                                                                             
  Q07812                              Bax                                      MAPKgroup     0.124                           0.676
                                                                                                                             
  Q13009                              Tiam-1                                   PKCgroup      0.315                           0.757
                                                                                                                             
  P05771                              PKCgroup                                 PDK-1         0.521                           0.957
                                                                                                                             
  P05129                              PKCgamma                                 PDK-1         0.456                           0.957
                                                                                                                             
  P28482                              ERK2                                     PDK-1         0.690                           0.957

\*IAP values were calculated for the kinase type (specificity class) at training procedure.

The scores obtained for the correctly predicted interactions varied from 0.013 to 0.915. It should be noted that several predictions were obtained for the superclass or subclass of the kinase type, which can be determined in TRANSPATH^®^entry (marked by asterisks).

All the interactions predicted with *P*~1~\> *P*~0~are given in the Additional file [1](#S1){ref-type="supplementary-material"}: Predicted kinase substrate interactions.

Application of predicted interactions for the reconstruction of signal cascades
-------------------------------------------------------------------------------

Cytokines and other signal molecules bind to their receptors on the cell surface and trigger cascades of phosphorylation events inside the cell, leading to the activation or inactivation of transcription factors. Then, these specific regulatory proteins are relocated to the cell nucleus and bind to DNA sites switching on and off their target genes. Prediction of kinase-substrate interactions enriches the knowledge on potential phosphorylation cascades in cells and helps to understand the molecular mechanisms of regulation of important cellular functions in response to extracellular signals.

The set of predicted 2656 kinase-substrate interactions was used for the enrichment of network analysis of signal transduction cascades in skin cells, whose activation is triggered by the cytokine TNF-alpha. Based on microarray data \[[@B26]\], we have previously analyzed 74 upregulated genes (FC \> 2.0) in the cell line HUVEC upon stimulation by TNF-alpha. We have also identified the transcription factor binding sites in the promoters of these up-regulated genes \[[@B27]\]. We have identified the most significantly overrepresented binding sites for several transcription factor\'s families like (NF-kappa B, STAT, AP-1, IRF, MEF2, OCT and FOX) by comparison with the promoters of the genes, whose expression has not been changed.

In order to reconstruct the TNF-alpha-triggered phosphorylation cascades leading to the activation of these transcription factors, we applied ExPlain™ to TRANSPATH^®^, before and after the enrichment by 2656 predicted kinase-substrate interactions.

For any set, we run twice the algorithm in downstream direction, each time starting with TNF ligand. The algorithm was stopped at reaching TF entries in the network less than 6 steps downstream off TNF. We compared two resulting networks and found that the newly predicted kinase-substrate interactions helped us to reconstruct potential signal cascades that activate several transcription factors in response to TNF, which could not be identified otherwise (Figure [3](#F3){ref-type="fig"}). Among such factors, we paid special attention to MEF-2A and STAT6 factors, which are known to be activated by p38alpha \[[@B28]\] and Jak2 \[[@B29]\], respectively. PAAS predicted that these two kinases can potentially be activated by PDK-1 (Figure [3](#F3){ref-type="fig"}, dashed arrows). Notably, with the newly predicted kinase-substrate interactions ExPlain™ reconstructed the signal cascade from TNF ligands to MEF-2A and STAT6 transcription factors identified by promoter analysis. This was not possible using the interactions documented in TRANSPATH^®^. Remarkably, there are evidences in literature on immunoprecipitation experiments showing that PDK-1 may associate with Jak2 and modulate the activity of Stat pathways \[[@B30]\]. The patent data have also shown that the immunoprecipitation experiments demonstrate the interaction between p38 and PDK-1 \[[@B31]\]. Further direct experimental studies for evaluation and validation of these predictions are necessary.

![**Signal transduction cascade from TNF ligands to transcription factors reconstructed by ExPlain™ system**. TNF ligand is depicted as orange triangle. Transcription factors (TFs, diamonds) are identified by promoter analysis of up-regulated genes upon TNF-alpha stimulation of HUVEC cell line. Dashed arrows represent the novel predicted kinase-substrate interactions helping to connect TNF ligands with TFs through cascades of phosphorylation events. All other arrows represent signal transduction interactions known in TRANSPATH^®^. The up-regulated molecules are red. The down-regulated molecules are green. Two underlined TFs can be reached from TNF ligands in less than 6 steps with the help of the novel kinase-substrate interactions only.](1471-2105-11-313-3){#F3}

The potential importance of MEF-2A and STAT6 transcription factors in activation of genes upon TNF treatment is demonstrated in Figure [4](#F4){ref-type="fig"}. We identified closely situated binding sites for these two factors in the promoters of genes characterizing extremely high fold change: VCAM1 (vascular cell adhesion molecule 1) (FC = 43.11), CCL20 (chemokine (C-C motif) ligand 20) (FC = 11.83) and TNFAIP3 (tumor necrosis factor, alpha-induced protein 3) (FC = 11.11). It is tempting to speculate that up-regulation of these genes upon TNF stimulation is triggered through the proposed here signal mechanism involving the phosphorylation of p38-alpha, Jak2 and other specific novel substrates by PDK-1 kinase.

![**Binding sites for MEF-2A and STAT6 transcription factors**. These binding sites are closely situated in promoters of three highly up-regulated genes upon TNF-alpha treatment. TF sites are found with ExPlain™ and position weight matrices (PWMs) from TRANSFAC^®^database. Sites are shown as arrows above the sequences of promoters. The names of PWMs are shown together with the obtained site score (shown in the brackets).](1471-2105-11-313-4){#F4}

Discussion
==========

The protein partner prediction is very important for the reconstruction of the cell cycle regulation network. This task is usually solved by the combination of functional characteristics and the search of specific sequence features. Significant sequence homology of the known kinase substrates and annotated protein should provide the most predictive ability. However, the large variety of proteins affected by the same kinases does not reveal the global sequence similarity.

We retrieved the kinase substrate sequences from Phosho.ELM database, as it is the most comprehensive informational resource that provides easy mining of experimentally established data. Though Phospho.ELM database contains detailed information on phosphorylated regions in the substrate sequences, we have used only the sequences classified by the kinases phosphorylating these proteins. The local similarity approach makes possible the recognition of similar regions of local sequences. We have considered that PAAS method reveals relatively short functional determinants by multiple projections of the sequences from the training set into the annotated sequence. The test with multiple divisions of the training set showed satisfactory results. When we used only human proteins removing the orthologous proteins, the results remained reasonable. So, the elimination of very similar proteins had slightly changed the kinase substrate recognitions.

The majority of existing methods for prediction of the kinase substrates is based on the recognition of the phosphorylation motifs. Corresponding sequence regions are experimentally determined. Collections of phosphorylated peptide sequences are used to construct Hidden Markov Models, Position Specific Scoring Matrices and other motif representations. Generally, the recognition properties of phosphorylation motifs are typically insufficient for the reproduction of substrate specificity \[[@B8]\]. The location of the kinase-docking motifs within the substrates and regulatory subunits (e.g. cyclines), substrate capturing non-catalytic interaction domain and other context information may significantly improve the prediction. The popular resource NetworKIN combines the consensus sequence motifs and protein-association networks. It increases the prediction accuracy up to 60-80% \[[@B32]\].

Our approach enables one to make predictions based only on the sequences of proteins, without any context data. It does not require the preliminary processing of the input data when the functional motifs should be extracted from the whole sequence. So, we showed that PAAS method can recognize protein classes consolidated by the same partners. This situation can be considered as common. Classes like LKB1, PDK-1 and EGFR substrates were recognized with very high accuracy. It can be explained by close homology of sequences in the classes. However, the classes characterized by higher variability (such as the CK2 or PKC group), were classified with the appropriate accuracy. Several kinase-specificity classes were not predicted with the appropriate accuracy (IAP \< 0.6) due to the kinase substrates variability.

Prediction performed for the set retrieved from TRANSPATH^®^database showed the possibility of our method to detect the unknown partners of certain proteins, representing a part of the known network of cell signal transduction. The results of prediction were confirmed by several TRANSPATH^®^annotations.

Reconstruction of signal pathways may be based on the prediction of interacting protein pairs. Shen et al., using SVM-based algorithm, have accurately predicted more than 80% of interacting pairs in the three networks including 16, 189 and 93 interacting pairs. These results can be used for composition of pathways \[[@B33]\]. In this work, the prediction of protein-protein interactions (PPI) is based on the comparison of query pair with the training set, presenting the known interacting pairs. Such approach is used in the majority of PPI methods \[[@B9]\] which showed the reasonable accuracy for the large training sets \[[@B10],[@B11]\]. Other authors predict the interacting proteins on the basis of interrelations of positions in the aligned sequence sets \[[@B8]\]. We applied the alternative approach when the proteins affected by the same kinase type are the class of kinase specificity. Thus, the prediction of kinase substrates is interpreted as classification task. It was done because significantly diverged proteins are affected by the same type of kinases presented with the small number of sequences.

In order to estimate the efficiency of our approach with regard to signaling pathways, we enhanced ExPlain™ by enriching TRANSPATH-derived data with additional PAAS-predicted interactions. The enriched interaction set was used for reconstruction of the potential signal cascades activating several transcription factors in response to TNF signaling. This approach helped us in finding the novel paths between TNF and its target genes in the cell that could not be identified otherwise. Certainly, these predictions require the experimental validation, but our study has clearly demonstrated the complementarities of approaches used by ExPlain™ and PAAS.

Conclusions
===========

PAAS method designed for the sequence-based recognition of functional protein classes may be used for the experimental data on the proteins participating in signal transduction. The on-line version of PAAS for prediction of protein kinase substrates is freely available at <http://www.ibmc.msk.ru/PAAS/>. Nevertheless the predicting results appeared to be very useful for the network enrichment and reconstruction of the signal pathways with protein-kinase substrate interactions by ExPlain™. We suggest that application of the proposed approach for the large-scale studies relative to other types of cell signal transduction should significantly help in the reconstruction of cell signaling pathways.
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###### Additional file 1

**Predicted kinase substrate interactions**. File contains pairs of substrate-kinase, predicted by the PAAS. Putative substrates extracted from the TRANSPATH^®^database are designated by UniProt Primary Accession Numbers. The kinase types are designated according to the Phospho.Elm database. The values of difference *P*~1~- *P*~0~are presented for prognosis estimations. So 38 kinase types recognized with IAP \> 0.6 and 186 putative substrates formed the 2656 pairs predicted with threshold of *P*~1~- *P*~0~= 0.
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Click here for file

Acknowledgements
================

This work was supported by FP6 (grant \"Net2Drug\": LSHB-CT-2007-037590) and grant \"SysCo\": no. 37231) and the Russian Foundation for Basic Research (Grant N 09-04-01281). We thank BIOBASE GmbH for providing access to TRANSPATH^®^database and ExPlain™ system. We would like also to thank Institute of Systems Biology <http://www.biouml.org>, whose support for the costs of publication we gratefully acknowledge.
